Scynexis issues voluntary nationwide recall of BREXAFEMME

The company states: “SCYNEXIS is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME, or ibrexafungerp tablets, to the consumer level in the US market due to potential cross contamination with a non-antibacterial ss-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME(R) tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance.”